In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioMarin pays $691mm in cash plus up to $160mm in earn-outs for Prosensa

Executive Summary

BioMarin Pharmaceutical Inc. is acquiring all the outstanding shares of Dutch biotech Prosensa Holding NV for $17.75 each (a 53% premium), valuing the transaction at $641mm. At closing, BioMarin will buy $50mm in Prosensa convertible debt; if the transaction fails, the note will convert into 4.4mm Prosensa shares.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies